Mark Ragosa, CHIEF FINANCIAL OFFICER at Kiniksa Pharmaceuticals International, plc (KNSA), sold 55,658 shares at $21.38 ($1.2M) on 2024-12-09, disclosed to the SEC on 2024-12-10.
Scheduled sale ($1.2M) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.27 | 8,969 | $191K | 16.1% |
| 2 | $21.27 | 8,969 | $191K | 16.1% |
| 3 | $21.38 | 18,860 | $403K | 33.9% |
| 4 | $21.38 | 18,860 | $403K | 33.9% |
| Total | $21.34 avg | 55,658 | $1.2M | 100% |
| Filing → |
| KNSA | SELL | 2026-01-09 | $503K | — | Filing → |
| KNSA | SELL | 2025-12-10 | $3.6M | — | Filing → |
| KNSA | SELL | 2025-11-14 | $815K | — | Filing → |